Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nicholas Adomakoh"'
Publikováno v:
Expert Review of Anti-infective Therapy. 21:375-385
Autor:
Andreas Karas, Areti Georgopali, Maria J G T Vehreschild, Oliver A. Cornely, Gbenga Kazeem, Nicholas Adomakoh, Benoit Guery
Publikováno v:
European journal of clinical microbiology & infectious diseases, vol. 38, no. 6, pp. 1187-1194
European Journal of Clinical Microbiology & Infectious Diseases
European Journal of Clinical Microbiology & Infectious Diseases
Poor outcomes following Clostridium difficile infection (CDI) have been associated with advanced age, presence of cancer and C. difficile PCR-ribotype 027. The impact of baseline risk factors on clinical outcomes was evaluated using data from the EXT
Autor:
Areti Georgopali, David A Enoch, Daniel Dedman, Tarita Murray-Thomas, Nick A Francis, Andreas Karas, Nicholas Adomakoh
Publikováno v:
The Journal of hospital infection. 106(4)
Summary Background Clostridioides difficile infection (CDI) increases the risk of complications and mortality. We assessed the magnitude of these outcomes in a large cohort of English patients with initial and recurrent CDI. Aim To compare the risk o
Autor:
Oliver A. Cornely, Gbenga Kazeem, Nicholas Adomakoh, Christopher Longshaw, Veli-Jukka Anttila, Jose Alejandro Palacios-Fabrega, Simon D. Goldenberg, Andreas Karas, Maria J G T Vehreschild, Benoit Guery, Areti Georgopali, Karen Bisnauthsing, José María Aguado, Francesco Menichetti
Publikováno v:
The Lancet Infectious Diseases. 18:296-307
Summary Background Clostridium difficile infection causes severe complications and frequently recurs. An extended-pulsed fidaxomicin regimen might facilitate sustained clinical cure by prolonging C difficile suppression and supporting gut microbiota
Autor:
Vladimir Ivashkin, Yashwant R. Mahida, Panagiotis Gargalianos-Kakolyris, Andreas Karas, Andreas Stallmach, Grażyna Rydzewska, Ingrid Michon, Areti Georgopali, Christoph Högenauer, Nicholas Adomakoh, Reiner Tretter, Philippe Marteau, Walter Reinisch
Publikováno v:
Journal of Antimicrobial Chemotherapy
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2018, 73 (12), pp.3430-3441. ⟨10.1093/jac/dky368⟩
Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2018, 73 (12), pp.3430-3441. ⟨10.1093/jac/dky368⟩
ObjectivesInflammatory bowel disease (IBD) poses an increased risk for Clostridium difficile infection (CDI). Fidaxomicin has demonstrated non-inferiority to vancomycin for initial clinical cure of CDI in patients without IBD; however, lack of data h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0210703b31349b34a02c4d61534b286
https://hal.sorbonne-universite.fr/hal-01976070/document
https://hal.sorbonne-universite.fr/hal-01976070/document
Autor:
Maria J G T Vehreschild, Oliver A. Cornely, Gbenga Kazeem, Nicholas Adomakoh, Areti Georgopali, Andreas Karas, Benoit Guery
Publikováno v:
Open Forum Infectious Diseases. 4:S539-S540